Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.

NCT06705023 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Myocardial Injury
LV Dysfunction
Coronary Artery Disease
Heart Failure

Interventions

BIOLOGICAL: Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)
OTHER: Continuation of patient's best guideline based medical treatment

Sponsor

Ralf Rothoerl

Collaborators

[object Object]
[object Object]
[object Object]